These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19580457)

  • 1. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget's disease of bone.
    Langston AL; Campbell MK; Fraser WD; MacLennan GS; Selby PL; Ralston SH;
    J Bone Miner Res; 2010 Jan; 25(1):20-31. PubMed ID: 19580457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Randomized Trial of Intensive Versus Symptomatic Management in Paget's Disease of Bone: The PRISM-EZ Study.
    Tan A; Goodman K; Walker A; Hudson J; MacLennan GS; Selby PL; Fraser WD; Ralston SH;
    J Bone Miner Res; 2017 Jun; 32(6):1165-1173. PubMed ID: 28176386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical determinants of quality of life in Paget's disease of bone.
    Langston AL; Campbell MK; Fraser WD; Maclennan G; Selby P; Ralston SH
    Calcif Tissue Int; 2007 Jan; 80(1):1-9. PubMed ID: 17205328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP; Ward LC; Stewart GO; Will RK; Criddle RA; Prince RL; Stuckey BG; Dhaliwal SS; Bhagat CI; Retallack RW; Kent GN; Drury PJ; Vasikaran S; Gutteridge DH
    Bone; 2004 Apr; 34(4):747-54. PubMed ID: 15050907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone.
    Merlotti D; Rendina D; Gennari L; Mossetti G; Gianfrancesco F; Martini G; De Filippo G; Avanzati A; Franci B; Campagna MS; Strazzullo P; Nuti R
    J Bone Miner Res; 2011 Mar; 26(3):512-8. PubMed ID: 20814970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis and management of Paget's disease of bone.
    Ralston SH; Langston AL; Reid IR
    Lancet; 2008 Jul; 372(9633):155-163. PubMed ID: 18620951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone turnover markers in Paget's disease of the bone: A Systematic review and meta-analysis.
    Al Nofal AA; Altayar O; BenKhadra K; Qasim Agha OQ; Asi N; Nabhan M; Prokop LJ; Tebben P; Murad MH
    Osteoporos Int; 2015 Jul; 26(7):1875-91. PubMed ID: 26037791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates in the management of Paget's disease.
    Ralston SH
    Bone; 2020 Sep; 138():115465. PubMed ID: 32512166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid for Paget's disease of bone.
    Maricic M
    Drugs Today (Barc); 2007 Dec; 43(12):879-85. PubMed ID: 18174973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone.
    Ohara M; Imanishi Y; Nagata Y; Ishii A; Kobayashi I; Mori K; Ito M; Miki T; Nishizawa Y; Inaba M
    J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
    J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.
    Cantrill JA; Buckler HM; Anderson DC
    Ann Rheum Dis; 1986 Dec; 45(12):1012-8. PubMed ID: 3813665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with pamidronate in the treatment of Paget's disease of bone.
    Gallacher SJ; Boyce BF; Patel U; Jenkins A; Ralston SH; Boyle IT
    Ann Rheum Dis; 1991 Dec; 50(12):930-3. PubMed ID: 1768163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paget's disease of bone and calcium homeostasis: focus on bisphosphonate treatment.
    Polyzos SA; Anastasilakis AD; Makras P; Terpos E
    Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):519-24. PubMed ID: 21811962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic and scintigraphic improvement after intravenous pamidronate treatment of Paget's disease of bone in patients with normal serum alkaline phosphatase levels.
    Ang G; Feiglin D; Moses AM
    Endocr Pract; 2003; 9(4):280-3. PubMed ID: 14561571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients with Paget's disease: a consensus document of the Belgian Bone Club.
    Devogelaer JP; Bergmann P; Body JJ; Boutsen Y; Goemaere S; Kaufman JM; Reginster JY; Rozenberg S; Boonen S;
    Osteoporos Int; 2008 Aug; 19(8):1109-17. PubMed ID: 18504638
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.